Summary
• Dare Bioscience, Inc. (DARE) shares rose 11% to $2.32 in pre-market trading following the announcement of its sildenafil cream, DARE TO PLAY™.
• The product, aimed at enhancing women’s sexual health, is now available for pre-order by prescription.
• Analysts maintain a “Buy” rating with a price target of $12, reflecting positive sentiment around the company’s new offering.
DARE Bioscience, Inc. (DARE) is trading at $2.32, reflecting an 11% increase from its previous close of $2.09 in pre-market action. The stock’s movement comes amid the company’s recent announcement concerning the commercial availability of its innovative product, DARE TO PLAY™ sildenafil cream.
Commercial Rollout Sparks Investor Interest
On December 10, Dare Bioscience reported that DARE TO PLAY™ sildenafil cream is now available for pre-order by prescription. This product is presented as the first evidence-based topical arousal cream for women, designed to increase genital blood flow rapidly and enhance arousal sensations based on clinically validated studies. The rollout of this unique non-hormonal formulation is a pivotal moment in women’s sexual health, potentially addressing a significant gap in this area of medicine.
The initial introduction of DARE TO PLAY™ is expected to stimulate both market demand and investor interest, marking an important step forward for the company.
Market Performance Overview
DARE has demonstrated notable market dynamics, with a recent weekly performance of 16.8% and a monthly performance of 7.7%. The stock shows a relative strength index (RSI) of 64.88, indicating it is approaching overbought territory. Average trading volume over the past 10 days has been approximately 191,238 shares, significantly higher than the average three-month volume of 142,892 shares.
The stock is currently trading above its 20-day simple moving average (SMA) of 15.9%, indicating strong momentum. However, it remains below its 200-day SMA, which stands at -15.1%.
Analyst Sentiment and Consumer Reception
Analysts maintain a “Buy” rating for DARE, with a price target maintained at $12 by HC Wainwright & Co. This assessment reflects optimism around the company’s products, particularly the newly launched cream—a factor that could influence future price movements.
Closing Summary
With strong initial interest in DARE’s latest product offering, the pre-market price increase suggests heightened investor enthusiasm. The stock’s performance will be closely monitored as traders assess how the commercial rollout of DARE TO PLAY™ influences its market trajectory in the upcoming sessions.